COLON CANCER NEWS TIPS & FEATURES


OMNI Health Media is a leading online provider of Daily Health News. OMNI’s Colorectal Cancer News provides summaries of developments in the prevention, screening, and management of Gastrointestinal Health Conditions as they are discovered and reported by physicians and scientists around the world. Our mission is to provide this news, including results of recent clinical trials evaluating new therapies and supportive care strategies in order to better educate patients and their caregivers, ensuring timely access to the best care available.
Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Colo-rectal Cancer

March 29, 2018

Larotrectinib Demonstrates 76 Percent Response Rate in TRK Fusion Cancers Including Colo-rectal Cancer

By cancerconnect cancerconnect

CancerConnect News: Clinical data from three ongoing larotrectinib (LOXO-101) clinical trials in patients whose tumors harbor tropomyosin receptor kinase (TRK) fusions demonstrating a 76 percent confirmed objective response rate (ORR) across tumor types, were published today in the New England Journal of Medicine after an initial summary presentation at the American Society of Clinical Oncology […]

View full entry

Tags: Colon Cancer, colorectal cancer, News Tips and Features, News Tips and Features Other, Rectal Cancer


Opdivo Combined with Yervoy Appears Promising for Patients with dMMR or MSI-H Advanced Colorectal Cancer

March 27, 2018

Opdivo Combined with Yervoy Appears Promising for Patients with dMMR or MSI-H Advanced Colorectal Cancer

By cancerconnect cancerconnect

CancerConnect News: New data from the phase 2 CheckMate -142 trial evaluating Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of patients with DNA mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer presentated at the 2018 Gastrointestinal Cancers Symposium in San Francisco, Calif., and simultaneously published in the Journal of Clinical Oncology […]

View full entry

Tags: Colon Cancer, colorectal cancer, News Tips and Features, News Tips and Features Other


NSAIDs Decrease Risk of Colorectal Cancer

September 12, 2017

NSAIDs Decrease Risk of Colorectal Cancer

By cancerconnect cancerconnect

Nonsteroidal anti-inflammatory drugs (NSAIDS) are medicines that are used for the treatment of a wide range of musculoskeletal illnesses including spinal disorders, osteoarthritis and inflammatory conditions like rheumatoid arthritis. NSAIDs effectively relieve pain, inflammation, and fever.  A number of treatment guidelines for osteoarthritis, rheumatoid arthritis, and chronic low back pain recommend the use of NSAIDs […]

View full entry

Tags: chronic low back pain, colorectal cancer, News Tips and Features, News Tips and Features Other, NSAIDs, osteoarthritis, rheumatoid arthritis


Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know

July 17, 2017

Personalized Precision Medicine Treatment of Colon Cancer: What Every Patient Should Know

By Anonymous User anonymous_user_10987

The purpose of precision cancer medicine is not to categorize or classify cancers solely by site of origin, but to define the genomic alterations in the cancer’s DNA that are driving that specific cancer.  Precision cancer medicine utilizes molecular diagnostic testing, including DNA sequencing, to identify cancer-driving abnormalities in a cancer’s genome. Once a genetic abnormality […]

View full entry

Tags: Biomarkers, BRAF, Carcinoembryonic Antigen, CEA, cetuximab, Colon Cancer, colorectal cancer, EGFR, epidermal growth factor receptor, Genetic Mutations, kras, Microsatellite Instability High


FDA Approves Vectibix® Precision Colon Cancer Medicine For Use In Advanced Colorectal Cancer

July 10, 2017

FDA Approves Vectibix® Precision Colon Cancer Medicine For Use In Advanced Colorectal Cancer

By cancerconnect cancerconnect

The U.S. Food and Drug Administration (FDA) has approved Vectibix® (panitumumab), a precision cancer medicine for the initial treatment of patients with wild-type RAS metastatic colorectal cancer.  Vectibix may be used as first-line therapy in combination with FOLFOX or as single agent therapy following disease progression after prior treatment with oxaliplatin, and irinotecan-containing chemotherapy.1 About […]

View full entry

Tags: colorectal cancer, EFGR, News Tips and Features, News Tips and Features Other, panitumumab, Precision Cancer Medicine, vectibix


Cancers Caught During Screening Colonoscopy are More Survivable

March 2, 2017

Cancers Caught During Screening Colonoscopy are More Survivable

By Anonymous User anonymous_user_10987

Patients whose colorectal cancer (CRC) is detected during a screening colonoscopy are likely to survive longer than those who wait until they have symptoms before having the test. The study, “Survival in patients with colorectal cancer diagnosed by screening colonoscopy,” looked at 312 patients in 10 gastroenterology practices in Germany, all aged 55 or older, […]

View full entry

Tags: Colon Cancer, colonoscopy, colorectal cancer, News Tips and Features, News Tips and Features Other, Rectal Cancer, screening, Screening/Prevention Colon Cancer, Screening/Prevention Rectal Cancer


Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

July 28, 2016

Addition of Eloxatin® Following Surgery Delays Cancer Progression in Certain Colorectal Cancers

By Anonymous User anonymous_user_10987

The addition of the chemotherapy combination consisting of Eloxatin (oxalipatin) plus 5-fluorouracil (5 FU) following surgery reduces the risk of cancer progression among patients with deficient mismatch repair (dMMR) stage III colorectal cancer. These results were recently published in the Journal of the National Cancer Institute. Among patients with colorectal cancer that has spread to […]

View full entry

Tags: 5fu, Adjuvant (I-III, A-C) Colon Cancer, Colon Cancer, colorectal cancer, crc, dmmr, eloxatin, mismatch repair, News Tips and Features, News Tips and Features Other, oxaliplatin, Rectal Cancer


Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

May 11, 2016

Herceptin® Plus Tykerb® Promising for HER2-Positive Colorectal Cancer

By Anonymous User anonymous_user_10987

The treatment combination consisting of Herceptin (trastuzumab) plus Tykerb (lapatinib) provides significant anti-cancer activity in colorectal cancer that overexpresses the human epidermal growth factor receptor 2 (HER2). These results were recently published in The Lancet Oncology. The HER2 receptor is a protein that is normally found on the surface of several different types of cells […]

View full entry

Tags: Colon Cancer, colorectal cancer, HER2-positive, Herceptin, lapatinib, News Tips and Features, News Tips and Features Other, Rectal Cancer, trastuzumab, Tykerb


View more articles like this
More news and in-depth Colon Cancer information

CONDITIONS OF THE GI TRACT